Biomarker for evaluating the immune status of never-smoker non-small cell lung cancer patients and a method of providing information on the immune status of never-smoking non-small cell lung cancer patients using the same

摘要

The present invention relates to a biomarker for determining the immune status of a non-smoking non-small cell lung cancer patient and a method for providing information on the immune status of a non-smoking non-small cell lung cancer patient using the same, and more particularly, to a non-smoking non-small cell lung cancer patient. The present invention relates to a method for providing information on the immune status of non-smoking non-small cell lung cancer patients by measuring the PTPN7 marker and PTPN7 expression level for determining the immune status. In the present invention, as a result of clustering by analyzing the genes of non-smoking non-small cell lung cancer patients, hot, intermediate-ECM-H (intermediate-ECM-H), intermediate-ECM -L (intermediate-ECM-L) and cold (cold) stages were confirmed to be classified into four clusters, and as a result of analyzing the genes for each stage, PTPN7 was used to determine the immune environment of non-smokers non-small cell lung cancer. It was confirmed that it is a biomarker. Therefore, the PTPN7 marker of the present invention can be utilized not only to determine the immune status of non-smoking non-small cell lung cancer patients, but also can provide information on treatment according to the immune status using the same.